Fibrinogen Like Protein 1NCT05929989
Cystatin D Fibrinogen Like Protein 1
An observational study of Fibrinogen Like Protein 1, run by Assiut University.
Trial summary
to detect role of cystatin D and fibrinogen like protein 1 in rheumatoid arthritis asses relationship between disease activity and cystatin D and fibrinogen like protein 1 Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Fibrinogen Like Protein 1
- What is being tested?
- ELISA TEST
- How many people
- 86 participants
- Where
- No sites listed yet
- Study dates
- Jan 2024to Jan 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: adult patient diagnosed with rheumatoid arthrits
Who may be able to join
- adult patient diagnosed for rheumatoid arthritis
Who cannot join
- patient with overlap syndrome indiviuals with other auto immune diseases
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Role of Cystatin D and Fibrinogen Like Protein 1 in Rheumatoid Arthritis and Their Relation to Disease Activity
to detect role of cystatin D and fibrinogen like protein 1 in rheumatoid arthritis asses relationship between disease activity and cystatin D and fibrinogen like protein 1
- Conditions
- Fibrinogen Like Protein 1
- Being tested
- ELISA TEST
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ELISA TESTDiagnostic test
ELISA TEST for cystatin D and fibrinogen like protein
| Study group | Role | What they receive |
|---|---|---|
| active disease | Not described Receives: Diagnostic Test: ELISA TEST | |
| control | Not described Receives: Diagnostic Test: ELISA TEST |
What is being measured
The primary outcome is the main question the study is designed to answer.
detect role of cystatin D and fibrinogen like protein 1
detect role of the two biomarkers and there relationship to rheumatoid arthriths
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jul 2023
- Study startJan 2024 (estimated)
- Primary completionJan 2026 (estimated)
- Study completionJan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Fibrinogen Like Protein 1Studies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 86 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Heba abd el salam selim, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05929989
- Sponsor's protocol ID
- cystatin D
- Status last verified
- Jun 2023
- First submitted
- 26 Jun 2023
- Last updated
- 5 Jul 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Lin WW, Ho KW, Su HH, Fang TF, Tzou SC, Chen IJ, Lu YC, Chang MS, Tsai YC, Liu ES, Su YC, Wang YT, Cheng TL, Huang HK. Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice. Front Immunol. 2021 Dec 16;12:767868. doi: 10.3389/fimmu.2021.767868. eCollection 2021.
PubMed 34975855Scherer HU, Haupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020 Jun;110:102400. doi: 10.1016/j.jaut.2019.102400. Epub 2020 Jan 22.
PubMed 31980337
Study at a glance
From the registry record, last updated by the sponsor on 5 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of Cystatin D and Fibrinogen Like Protein 1 in Rheumatoid Arthritis and Their Relation to Disease Activity
- ClinicalTrials.gov ID
- NCT05929989
- Acronym / sponsor ID
- cystatin D
- Conditions
- Fibrinogen Like Protein 1
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 86 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Jan 2024 (estimated)
- Primary completion
- Jan 2026 (estimated)
- Study completion
- Jan 2026 (estimated)
- First posted
- 5 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
to detect role of cystatin D and fibrinogen like protein 1 in rheumatoid arthritis asses relationship between disease activity and cystatin D and fibrinogen like protein 1
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| active disease | – | Diagnostic Test: ELISA TEST |
| control | – | Diagnostic Test: ELISA TEST |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- adult patient diagnosed with rheumatoid arthrits
Key inclusion criteria (1 listed)
- adult patient diagnosed for rheumatoid arthritis
Key exclusion criteria (1 listed)
- patient with overlap syndrome indiviuals with other auto immune diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ELISA TESTELISA TEST for cystatin D and fibrinogen like protein | Diagnostic test | active disease, control |
Primary outcome
detect role of cystatin D and fibrinogen like protein 1
Time frame: one year
detect role of the two biomarkers and there relationship to rheumatoid arthriths
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jul 2023.
- Background: PubMed 34975855Lin WW, Ho KW, Su HH, Fang TF, Tzou SC, Chen IJ, Lu YC, Chang MS, Tsai YC, Liu ES, Su YC, Wang YT, Cheng TL, Huang HK. Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice. Front Immunol. 2021 Dec 16;12:767868. doi: 10.3389/fimmu.2021.767868. eCollection 2021.
- Results publication: PubMed 31980337Scherer HU, Haupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020 Jun;110:102400. doi: 10.1016/j.jaut.2019.102400. Epub 2020 Jan 22.
Related trials for Fibrinogen Like Protein 1
Active, not recruitingObservational study
Cardiac Displacement From Third Trimester to Early Childhood
IUGR, Fetal Growth Retardation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Fibrinogen Like Protein 1, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact heba abdelsalam selim (00201222260723, hebaselim85@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
detect role of cystatin D and fibrinogen like protein 1 (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05929989, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jul 2023.